The usual Tudorza Pressair dosage for COPD is 1 inhalation twice daily. Specific dosages may vary depending on your individual symptoms and other medications you take. It’s important to use the ...

Forest Laboratories and Almirall Announce FDA Approval of Tudorza(TM) Pressair(TM) for the Long-Term Maintenance Treatment of COPD NEW YORK & BARCELONA, Spain, Jul 23, 2012 -- Forest Laboratories, Inc ...

Forest Laboratories, Inc.Frank J. Murdolo, 212-224-6714Vice President - Investor Relationsor Media information:enquiries:KetchumSonia San Segundo, 00-34-91-788-32-00orInvestor Relations:AlmirallJordi ...

TUDORZA PRESSAIR (aclidinium bromide) 400mcg inhalation powder by Forest Laboratories Forest Laboratories and Almirall announced that the FDA has approved Tudorza Pressair (aclidinium bromide ...

The U.S. Food and Drug Administration today approved Tudorza Pressair (aclidinium bromide) for the long-term maintenance treatment of bronchospasm (narrowing of the airways in the lung) associated ...

(HealthDay) -- The Tudorza Pressair (aclidinium bromide) inhaler has been approved by the U.S. Food and Drug Administration to treat narrowing of the lung airways associated with chronic obstructive ...

The FDA on Monday approved Tudorza™ Pressair™ (aclidinium bromide inhalation powder) for long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), ...

Aclidinium bromide 400mcg/actuation; dry powder for oral inhalation. Before use, press green button on inhaler all the way down, then release green button. Stop and check control window to make sure ...

Forest Laboratories and Almirall announce commercial availability of Tudorza™ Pressair™ in US pharmacies New treatment for COPD now available in US pharmacies NEW YORK & BARCELONA, Spain--(BUSINESS ...

NEW YORK & BARCELONA, Spain--(BUSINESS WIRE)-- Forest Laboratories, Inc. (NYS: FRX) and Almirall, S.A. (ALM:MC) announced today that Tudorza™ Pressair™ (aclidinium bromide inhalation powder) 400mcg is ...